Ebola Bundibugyo in Nigeria: USMLE High-Yield Review

Nigerian officials and the World Health Organization have confirmed that an Ebola case in a woman diplomat in Abuja is caused by the Bundibugyo strain, the same virus behind the large outbreak in the Democratic Republic of Congo (DRC). Nigeria is now the fourth African country affected. For Bundibugyo virus there is still no vaccine and no specific treatment. This is a news report, not a study, but it is a good reason to review filovirus biology for Step 1 and Step 2 CK.

What happened

According to the Medical Xpress report (based on AFP), the patient traveled from Uganda to Abuja on Oct. 3, and the Nigeria Centre for Disease Control and Prevention (NCDC) announced the case. The NCDC's laboratory director said three levels of testing were done, all molecular, and all identified the Bundibugyo strain. The WHO also confirmed the strain.

An official said the patient has deteriorated into "multiorgan failure." The nationality of the diplomat was not disclosed. Nigeria has identified 44 contacts, who are being monitored, and is looking for others who may have been exposed. The WHO said infection prevention and control was being "ramped up" at the private hospital where the patient sought care.

The wider outbreak, as reported:

• DRC: more than 9,000 confirmed cases and 4,381 deaths since mid-May, according to health authorities. This is described as the deadliest Ebola epidemic in the country's history.
• Kenya: nine cases since Oct. 6.
• Uganda: declared Ebola-free by the WHO in August after 20 cases, almost all in people who had traveled from the DRC.
• Africa CDC: its director general, Jean Kaseya, called the outbreak "an extremely serious threat" and the most geographically widespread Ebola outbreak in history, spanning three regions of Africa. He said fatality rates in the DRC are edging toward 50%. A ministerial meeting is planned for next Wednesday.

Why it matters

Nigeria has relevant experience. In 2014 the first case was detected in Lagos, a city of over 20 million. A swift response, supported by international organizations, brought that outbreak under control within 21 days, with 19 infections and seven deaths. That contrasted with the West African epidemic, which killed more than 11,000 people between late 2013 and 2016.

A former NCDC director told AFP he was confident Nigeria could contain the new outbreak, but said success would depend on funding and political commitment. Cross-border spread is a concern because the strain has no licensed countermeasures. Control therefore depends on classic public health tools: rapid diagnosis, isolation, contact tracing and infection control.

For readers outside Africa: this report describes one confirmed case in Nigeria. It does not describe widespread transmission there.

What to know for the USMLE: Ebola, Bundibugyo and Filoviridae

• Virology: Filoviridae are enveloped, filamentous, non-segmented negative-sense ssRNA viruses. Ebola and Marburg are the key members. Bundibugyo is one species within the Ebola genus, alongside Zaire, Sudan, Taï Forest and Reston. Reston infects primates but is not known to cause human disease.
• Reservoir: Fruit bats are the suspected natural reservoir. Outbreaks start with spillover from animals, then spread person to person.
• Transmission: Spread is by direct contact with blood or body fluids of symptomatic or deceased patients, through broken skin or mucous membranes. It is not classically airborne. Infectiousness rises as illness progresses, and unsafe funeral practices and healthcare-associated spread are classic amplifiers.
• Incubation: About 2–21 days. This is why contacts are monitored for 21 days, and why a travel history within that window matters on exam vignettes.
• Pathogenesis: The virus infects monocytes, macrophages and dendritic cells first, then spreads to the liver, spleen and endothelium. Viral proteins (for example VP35) blunt the type I interferon response. Infected macrophages release cytokines and tissue factor, which drives vascular leak, DIC and shock. Lymphocyte apoptosis contributes to immune failure. This explains the multiorgan failure seen in severe disease.
• Clinical picture: Abrupt fever, myalgia, headache, then severe vomiting and watery diarrhea with volume depletion. Hemorrhagic manifestations occur in a subset and usually late. Typical labs: leukopenia, thrombocytopenia, elevated AST and ALT (AST often higher), coagulopathy.
• Diagnosis: RT-PCR on blood is the standard. It is a molecular test, as in this report. Antigen and antibody tests have supporting roles. Specimens need high-containment handling.
• Management principles: Care is mainly supportive: fluid and electrolyte replacement, correction of coagulopathy, treatment of co-infections. Approved vaccines and monoclonal antibodies target Zaire ebolavirus specifically. That is why, as the report notes, Bundibugyo has no vaccine or specific therapy.
• Infection control: Isolation, strict PPE (gloves, gown, eye protection, respirator or mask per protocol), safe burial, contact tracing and monitoring. For a board question about a febrile returning traveler with possible exposure, think about isolation before any further workup.
• Differential in West and Central Africa: Malaria (always consider first in a febrile traveler), Lassa fever (an arenavirus endemic in Nigeria, with a rodent reservoir and ribavirin as a treatment), Marburg, Crimean-Congo hemorrhagic fever, yellow fever, dengue and typhoid.

Limitations

• This is a news report, not a peer-reviewed study. Figures come from health authorities and officials quoted by AFP. They may change as testing and reporting evolve.
• Case-fatality figures are crude. The ratio of 4,381 deaths to more than 9,000 confirmed cases comes to just under 49% at most. In an ongoing outbreak, some patients still have unknown outcomes, so this is not a final case-fatality rate. The source also does not describe how deaths were attributed.
• Only one case in Nigeria is described. The source does not explain where the patient was exposed, her exact clinical course beyond multiorgan failure, or whether any contacts have become ill.
• Reassurance from the past is not a guarantee. Nigeria's 2014 success is encouraging. But the source quotes officials saying that outcomes depend on funding, command structures and timely action.
• The strain-specific lack of countermeasures is stated by the WHO in the source. The source does not discuss any candidate products or trials.

FAQ

What is the Bundibugyo strain of Ebola?

It is one of the Ebola species in the family Filoviridae, named after a district in Uganda where it was first recognized. It causes a hemorrhagic-type illness similar to other Ebola viruses. According to the source, it has no vaccine or specific treatment.

Is Ebola airborne?

No. Ebola is classically spread through direct contact with body fluids of an infected person, or contaminated materials. This is why contact precautions, PPE and isolation are central to infection control.

Why does the 21-day period matter for Ebola?

The incubation period is up to 21 days. Contacts are therefore monitored for that long. In the source, Nigeria's 2014 outbreak was brought under control within 21 days. Nigeria is now monitoring 44 contacts in the current case.

Key takeaways

• Nigeria's Ebola case in a diplomat who traveled from Uganda was confirmed by molecular testing as Bundibugyo virus, linked to the DRC outbreak. The DRC has reported more than 9,000 confirmed cases and 4,381 deaths. Four African countries are now affected.
• Bundibugyo has no vaccine and no specific treatment, so control relies on isolation, contact tracing (44 contacts in Nigeria) and strict infection prevention.
• For USMLE, focus on filovirus structure (enveloped negative-sense ssRNA), transmission by body fluids, the 2–21 day incubation, macrophage tropism with DIC and shock, RT-PCR diagnosis, and the fact that licensed countermeasures target Zaire ebolavirus.